Skip to content

US · RGEN · MEDICAL - INSTRUMENTS & SUPPLIES

Repligen Corporation (RGEN) intrinsic value and stock valuation

$163.81as of 2026-11-21 · Mkt cap 8.95B

Data updated · price as of 2026-11-21

Strongly overvaluedIC value is more than 50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Repligen Corporation DCF and intrinsic value

InvestorsCraft values RGEN with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from RGEN’s statements →

Repligen Corporation Graham Number

Graham Number: $27.07d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Instruments & Supplies Waltham, MA 02453 repligen.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$738.3M+15% 5y CAGRd
20112025
Net income
$48.9M-4% 5y CAGRd
20112025
Free cash flow
$93.9M+20.9% 5y CAGRd
20112025
Total equity
$2.11B+6.6% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$738.3M$634.4M$632.4M$801.5M$670.5M
Operating income$59.6M-$-35.11M$47.7M$224.7M$167.3M
Net income$48.9M-$-25.51M$35.6M$186M$128.3M
EPSd$864.4K-$-456.02K$631.4K$3.24M$2.24M
Operating cash flow$117.4M$175.4M$113.9M$172.1M$119M
Capital expenditure-$-23.52M-$-32.91M-$-38.99M-$-133.35M-$-67.09M
Free cash flow$93.9M$142.5M$74.9M$38.7M$51.9M
Total assets$2.95B$2.83B$2.83B$2.53B$2.36B
Total debt$690M$686.3M$711.8M$423M$366.1M
Net debt$123.9M-$-71.11M-$-39.52M-$-100.5M-$-237.76M
Total equity$2.11B$1.97B$1.96B$1.91B$1.75B
Cash and short-term investments$767.6M$757.4M$751.3M$623.8M$603.8M
Income statement
20252024202320222021
Revenue$738.3M$634.4M$632.4M$801.5M$670.5M
Cost of revenue$390.6M$359.8M$353.9M$345.8M$279.3M
Gross profit$347.6M$274.6M$278.4M$455.7M$391.3M
Research and development expenses$54.2M$43.2M$42.7M$43.9M$34.3M
Selling, general and administrative expenses$290.5M$263.4M$218.6M$215.8M$183.9M
Other expenses-$-56.64M$3.19M-$-30.57M-$-28.73M$5.87M
Operating expenses$288.1M$309.8M$230.7M$231M$224M
Cost and expenses$678.7M$669.6M$584.7M$576.9M$503.3M
Interest income$27.6M$0.00$0.00$6.98M$180K
Interest expense$23.2M$22.6M$10M$2.98M$12.7M
Depreciation and amortization$78.8M$86.6M$86.1M$57M$38.5M
Ebitda$164.3M$80.3M$145.3M$277.3M$203.3M
Operating income$59.6M-$-35.11M$47.7M$224.7M$167.3M
Total other income/expenses, net$2.81M$8.08M$9M-$-5.53M-$-13.71M
Income before tax$62.4M-$-27.04M$56.7M$219.1M$153.5M
Income tax expense$13.5M-$-1.52M$21.1M$33.2M$25.3M
Net income$48.9M-$-25.51M$35.6M$186M$128.3M
Weighted average shares outstanding$56.2M$55.9M$55.7M$55.5M$55M
Weighted average diluted shares outstanding$56.6M$55.9M$56.4M$57.5M$57.3M
Balance sheet
20252024202320222021
Cash and short-term investments$767.6M$757.4M$751.3M$623.8M$603.8M
Net receivables$158.6M$134.1M$124.2M$116.3M$117.4M
Inventory$170.5M$143M$202.3M$238.3M$184.5M
Total current assets$1.14B$1.07B$1.11B$998.1M$931.7M
Property, plant and equipment, net$306.2M$333.1M$323M$315.7M$226.5M
Goodwill and intangible assets$1.5B$1.43B$1.39B$1.22B$1.2B
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$1.81B$1.76B$1.72B$1.53B$1.43B
Total assets$2.95B$2.83B$2.83B$2.53B$2.36B
Accounts payable$30M$32.1M$19.6M$27.6M$36.2M
Short-term debt$21.6M$15.1M$75.1M$291.6M$263.6M
Deferred revenue$14.6M$13.2M$17.1M$19.3M$14.7M
Total current liabilities$135.8M$126.8M$164.9M$404.2M$375.3M
Long-term debt$668.4M$671.1M$636.7M$131.4M$102.5M
Deferred revenue, non-current$1.54M$0.00$0.00$0.00$0.00
Total non-current liabilities$707.7M$730.2M$701.4M$216.7M$233M
Capital lease obligations$126.2M$160.7M$132.2M$138.4M$110.8M
Total liabilities$843.6M$857M$866.3M$620.9M$608.3M
Common stock$560K$560K$560K$560K$550K
Retained earnings$456.3M$407.4M$432.9M$397.3M$194.1M
Accumulated other comprehensive income (loss)-$-2.53M-$-52.53M-$-37.81M-$-34.39M-$-16.89M
Total equity$2.11B$1.97B$1.96B$1.91B$1.75B
Total investments$201.6M$0.00$0.00$100.3M$0.00
Total debt$690M$686.3M$711.8M$423M$366.1M
Net debt$123.9M-$-71.11M-$-39.52M-$-100.5M-$-237.76M
Cash flow statement
20252024202320222021
Net income$48.9M-$-25.51M$41.6M$186M$128.3M
Depreciation and amortization$97M$86.6M$68.1M$57M$38.5M
Stock-based compensation$32.6M$48.1M$25.6M$27.3M$27.5M
Change in working capital-$-50.88M$60.9M-$-8.64M-$-69.84M-$-102.13M
Accounts receivable-$-17.16M-$-14.03M-$-3.31M-$-3.6M-$-46.52M
Inventory-$-14.95M$56.9M$41M-$-57.2M-$-89.78M
Accounts payable-$-4.15M$12.9M-$-9.8M-$-8.2M$19.5M
Net cash provided by operating activities$117.4M$175.4M$113.9M$172.1M$119M
Investments in property, plant and equipment-$-23.52M-$-25.68M-$-36.22M-$-84.83M-$-67.09M
Acquisitions, net-$-70.33M-$-54.77M-$-186.64M$0.00-$-149.89M
Net cash used for investing activities-$-298.47M-$-86.38M-$-123.28M-$-233.24M-$-221.17M
Common stock issued$3.18M$4.29M$1.08M$3.71M$3.88M
Common stock repurchased$0.00$0.00-$-14.39M$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-15.21M-$-82.9M$249M-$-13.34M$960K
Net change in cash-$-191.33M$6.03M$227.9M-$-80.36M-$-113.48M
Cash at end of period$566M$757.4M$751.3M$523.5M$603.8M
Operating cash flow$117.4M$175.4M$113.9M$172.1M$119M
Capital expenditure-$-23.52M-$-32.91M-$-38.99M-$-133.35M-$-67.09M
Free cash flow$93.9M$142.5M$74.9M$38.7M$51.9M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Repligen Corporation

        Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.

        CEO
        Olivier Loeillot
        Employees
        2K
        Beta
        1.06

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Repligen Corporation (RGEN)?

        Repligen Corporation (RGEN) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is RGEN undervalued?

        RGEN trades at a price of $163.81 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.